Malaria Vaccines for the World

2-4 May 2016, Leiden University Medical Center, Leiden, The Netherlands

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Monday 2nd May 2016

07.45 Onwards
Registration & Coffee

Welcome Address
Dean of LUMC, Leiden

Session 1:
General Plenary Session I

Session Leader: Ogobara Doumbo (University of Bamako, Bamako, Mali)

‘Multi-component malaria vaccines: Challenges and new solutions’
Adrian Hill (The Jenner Institute, University of Oxford, Oxford, UK)

‘PfSPZ Vaccine: The March Toward Licensure’
Steve Hoffman (Sanaria Inc., Rockville, Maryland, USA)

‘PATH Malaria Vaccine Initiative transmission-blocking vaccine strategy: Challenges and recent progress’
C. Richter King (PATH Malaria Vaccine Initiative, Washington DC, USA)

Coffee Break & Poster Set-Up

Session 2:

Session Leader: Chris Ockenhouse (PATH, Seattle, Washington, USA)

‘Session Introduction’
Chris Ockenhouse (PATH, Seattle, Washington, USA)

‘Designing epidemiological studies for the post approval plan of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries’
Laurence Baril 1, Jean-Yves Pirçon 1, Marie-Cécile Bozonnat 2, Valérie Haine 3, Effua Usuf 4, Elodie Garric 1 and Yolanda Guerra 1 on behalf of the RTS,S Safety Post Approval Plan Partnership Committee (1 GSK Vaccines, Wavre, Belgium; 2 4 Clinics, Paris, France, 3 Keyrus Biopharma, Lasne, Belgium; 4 Consultant for GSK Vaccines)

‘Addressing the methodological and logistical challenges of performing malaria vaccine effectiveness studies in sub-Saharan African countries’
Jean-Yves Pirçon and Laurence Baril (GSK Vaccines, Wavre, Belgium)

‘Mathematical modelling to prioritize second generation malaria vaccines: Insights following from mathematical modelling prior to RTS,S recommendation’
Melissa A. Penny and Thomas A. Smith (Swiss Tropical and Public Health Institute, Basel, Switzerland and University of Basel, Basel, Switzerland)

‘Decreasing RTS,S vaccine efficacy with increase in genetic mismatch of malaria, yet some efficacy remains against highly mismatched malaria’
Michal Juraska 1, Daniel E. Neafsey 2, Trevor Bedford 1, David Benkeser 1, Marc Lievens 3, Bronwyn MacInnis 2, Sarah K. Volkman 2,4, Christian F. Ockenhouse 5, Peter B. Gilbert 1 and Dyann F. Wirth 2,4 (1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; 2 Broad Institute of MIT and Harvard; 3 GlaxoSmithKline Vaccines; 4 Harvard T.H. Chan School of Public Health; 5 PATH Malaria Vaccine Initiative, Washington DC, USA)

‘Benefit-risk balance of the RTS,S/AS01 malaria vaccine candidate and plans to address remaining questions’
Lode Schuerman, Elodie Garric, Pascale Vandoolaeghe and Yolanda Guerra Mendoza (GSK Vaccines, Wavre, Belgium)

Session Discussion

Lunch Break & Posters

Session 3:
Pre-erythrocytic Vaccines I

Session Leader: Steve Hoffman (Sanaria Inc., Rockville, Maryland, USA)

Session Introduction
Steve Hoffman (Sanaria Inc., Rockville, Maryland, USA)

‘A unique collaborative approach to successful malaria vaccine development: Lessons from the international PfSPZ Consortium’
Peter F. Billingsley for the International PfSPZ Consortium

‘Long term heterologous protection: The pot of gold at the end of the malaria vaccine rainbow’
Kirsten E. Lyke and Thomas L. Richie for the International PfSPZ Consortium

‘Successful establishment of a PfSPZ vaccine immunization regimen that protects non-immune, short-term travellers against Pf malaria’
J.E. Epstein for the International PfSPZ Consortium (Presented by Kirsten E. Lyke)

‘Manufacturing PfSPZ vaccines for malaria elimination’
B.K.L. Sim, A. Manoj, A. Eappen, T. Li, E.R. James, S. Chakravarty, M. Li, R. Stafford, A. Ruben, Y. Wu, P.F. Billingsley and S.L. Hoffman (Sanaria Inc., Rockville, Maryland, USA and Protein Potential LLC, Rockville, Maryland USA)

‘Identification of protection associated HLA-allele specific epitopes within standard and novel Plasmodium falciparum antigens in human research subjects immunized with radiation attenuated sporozoites’
Martha Sedegah 1, Santiago Carmona 2, Maria Belmonte 1, Arnel Belmonte 1, Harini Ganeshan 1, Jun Huang 1, Sandra Inoue 1, Rachael Velasco 1, Bradley Hickey 1, Nimfa Teneza-Mora 1, Joanne Lumsden 1, Bjoern Peters 2 and Eileen Villasante 1 (1 Naval Medical Research Center, Silver Spring, Maryland, USA; 2 La Jolla Institute for Allergy and Immunology, La Jolla, California, USA)

‘Safety and efficacy of immunization by mosquito bite with radiation attenuated sporozoites evaluated in a phase 1 clinical trial: Final results’
Nimfa Teneza-Mora 1, Bradley Hickey 1, Sharina Reyes 2, Joanne Lumsden 2, Jo Glenna Banania 2, Charlotte Fedders 2, Yolanda Alcorta 2, Anatalio Reyes 2, Carlos Vasquez 2, Santina Maiolatesi 2, Harini Ganeshan 2, Jun Huang 2, Maria Belmonte 2, Arnel Belmonte 2, Esteban Abot 2, Alexandra Singer 1, Cindy Tamminga 2, James Moon 3, Michelle Spring 3, Patrick Twomey 3, Megan Dowler 3, Lindsay Garver 3, Silas Davidson 3, Martha Sedegah 1, Thomas Richie 1, Eileen Villasante 1 and Judith Epstein 1 (1 Naval Medical Research Center, Silver Spring, Maryland, USA; 2 Henry M. Jackson Foundation, Bethesda, Maryland, USA; 3 Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

Session Discussion

Tea Break & Posters

Session 4:
Pre-erythrocytic Vaccines II

Session Leader: Adrian Hill (University of Oxford, Oxford, UK)

Session Introduction
Adrian Hill (University of Oxford, Oxford, UK)

‘Viral vector malaria vaccines induce potent T cell and antibody responses in West African infants’
Katie Ewer (University of Oxford, Oxford, UK)

‘Induction of high levels of liver-resident CD8+ T-cells that protect against liver-stage malaria’
Anita Gola 1, Adam A. Walters 1, Benedict R. Halbroth 1, Ahmed M. Salman 1,2, Shahid M. Khan 2, Chris J. Janse 2, Alexandra J. Spencer 1 and Adrian VS Hill 1 (1 Jenner Institute, University of Oxford, Oxford, UK; 2 Leiden University Medical Center, Leiden, The Netherlands)

‘Clinical evaluation of the cell-traversal protein for ookinetes and sporozoites from Plasmodium falciprum (pfceltos) vaccine in a phase 1 trial with controlled human malaria infection’
Jason W. Bennett 1, Donna Tosh 1, Elke S. Bergmann-Leitner 1, Kristopher Paolino 1, Jason A. Regules 1, Elizabeth Duncan 1, Patrick Twomey 1, James E. Moon 1, April Kathcart 1, Heather E. Hosie 1, Casey K. Storme 1, Michele D. Spring 1, Kevin Hauns 1, Jack Komisar 1, Aziz Qabar 1, Silas Davidson 1, Christian F. Ockenhouse 4, Johan Vekemans 2, Lorraine Soisson 3, Ripley Ballou 2, Carter Diggs 3, Norman C. Waters 1, Robert M. Paris 1 and Evelina Angov 1 (1 Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 2 GSK Vaccines, Rixensart, Belgium; 3 United States Agency for International Development, Washington DC, USA; 4 PATH Malaria Vaccine Initiative (MVI), Washington DC, USA)

‘Why high numbers of CD8+ T cells are required to mediate protection against liver-stage malaria’
Alexandra J. Spencer, Rhea J. Longley, Anita Gola, Teresa Lambe and Adrian V.S. Hill (The Jenner Institute, University of Oxford, Oxford, UK)

‘Evaluation of Plasmodium falciparum SPECT-1 as a novel pre-erythrocytic vaccine candidate’
Ahmed M. Salman 1,2, Ana Rodríguez-Galán 1, Naif Khalaf Alharbi 1, Florian Brod 1, Aadil El Turabi 1, Paulo Bettencourt 1, Alexandra J. Spencer 1, Chris J. Janse 2, Shahid M. Khan 2 and Adrian V.S. Hill 1 (1 The Jenner Institute, University of Oxford, Oxford, Oxfordshire, UK; 2 Leiden Malaria Research Group, LUMC, Leiden, The Netherlands)

Session Discussion

MVW 2016 Poster Session & Welcome Drinks


MVW 2016 Delegates

Login details will be supplied after you have registered for the event.

MVW 2016 Sponsors

  • Malaria World
  • Aldevron
  • Malaria World Journal
  • MVI Path
  • Malaria No More
  • EVI
  • Leiden University Medical Center
  • Sanaria
  • Inovio Pharmaceuticals

MVW 2016 Downloads

MVW 2016 Leaflet

MVW 2016 Mailing List

E-mail Address
What is 3+2-1?